| Pegasys (pegylated interferon α -2a) / Roche |
NCT00221286: Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients |
|
|
| Terminated | 3 | 2 | Europe | pegylated interferon alfa-2a, tenofovir DF / emtricitabine combination therapy, pegIFN / TDF / FTC combination therapy | University Hospital, Bonn, Hoffmann-La Roche | Chronic Hepatitis B, HIV Infections | 01/07 | 01/07 | | |
NCT00296972: Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication |
|
|
| Terminated | 3 | 100 | Canada | peg interferon plus ribavirin | University Health Network, Toronto, Hoffmann-La Roche | Chronic Hepatitis C, HIV Infections | | 04/07 | | |
NCT00122616: Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C |
|
|
| Completed | 3 | 52 | Europe | Peginterferon alpha-2a (Pegasys®), Ribavirin, HIV antiretroviral therapy | French National Agency for Research on AIDS and Viral Hepatitis, Hoffmann-La Roche | HIV Infections, Hepatitis C, Chronic | 03/09 | 03/09 | | |
NCT01479868: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1 |
|
|
| Completed | 3 | 109 | US, Canada, Europe | TMC435, Pegylated interferon alpha-2a, Ribavirin | Janssen R&D Ireland | Hepatitis C Virus Genotype-1 | 08/13 | 08/13 | | |
|
|
|
|
|
NCT01471574 / 2011-003067-30: Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus |
|
|
| Completed | 3 | 549 | US, Canada, Europe, RoW | Daclatasvir, BMS-790052, Ribavirin, Copegus®, PEG-Interferon alfa 2a, Pegasys®, Pegylated interferon | Bristol-Myers Squibb | Hepatitis C, Genotype 1 | 06/14 | 09/14 | | |
HB01EMVIPEG, NCT00391638: Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients |
|
|
| Completed | 2/3 | 56 | Europe | TRUVADA (EMTRICITABINE + TENOFOVIR DF), PEGASYS 180μg (Interféron pégylé alpha -2a) | French National Agency for Research on AIDS and Viral Hepatitis, Gilead Sciences, Roche Pharma AG | Hepatitis B, HIV Infections | 05/11 | 10/12 | | |
No, NCT01006031 / 2009-009438-34: Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous nresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4 |
|
|
| Completed | 2/3 | 25 | Europe | Pegylated interferon alfa-2a and Ribavirin, Pegasys, Copegus | Sociedad Andaluza de Enfermedades Infecciosas | Liver Cirrhosis, Hepatitis C Virus, HIV Infection | 12/11 | 12/11 | | |
